Tuesday, November 17, 2026

SGC Partners and Bukwang Join Forces...Expand Bio and Healthcare Investments

Input
2026-11-17 09:51:19
Updated
2026-11-17 09:51:19
SGC Partners and Bukwang signed an MOU at Bukwang’s headquarters on the 16th to strengthen investment and business cooperation in the bio and healthcare sectors. SGC Partners CEO Seo Young-hyun (right) and Bukwang CEO Lee Je-young (left) pose for a commemorative photo. Provided by SGC Group

[Financial News] SGC Partners is joining forces with Bukwang to identify promising companies and expand investment in the bio and digital healthcare sectors.
On the 17th, SGC Partners said the two companies had signed a strategic MOU at Bukwang’s headquarters on the 16th to strengthen investment and business cooperation in the bio and healthcare sectors.
The agreement was designed to combine SGC Partners’ capabilities in identifying venture companies and managing investments with Bukwang’s expertise in pharmaceutical and biotech R&D and its experience commercializing medicines.
Under the agreement, the two companies will jointly identify domestic and international bio and digital healthcare startups and venture companies, and assess investment opportunities in stages.
The plan goes beyond simply identifying financial investment opportunities to comprehensively assess the technological competitiveness and business growth prospects of potential investee companies. The two companies will also explore opportunities for strategic business ties, including joint R&D and technology adoption, through cooperation with Bukwang.
The two companies also plan to assess the newly identified companies’ longer-term growth prospects, including global expansion, based on their technological and business competitiveness.
An SGC Partners representative said, “In the bio and healthcare industries, it is important not only to identify companies with innovative technologies but also to have the capabilities to turn those technologies into actual businesses.” The representative added, “Through this agreement, we will draw on Bukwang’s R&D capabilities and commercialization experience to assess promising companies’ technologies and growth prospects more concretely, and expand opportunities that link investment with business cooperation.”
A Bukwang representative said, “We will identify promising biotech companies by combining SGC Partners’ investment network with Bukwang’s capabilities in new drug R&D and commercialization.” The representative added, “We plan to expand practical open-innovation opportunities, including joint R&D and technology adoption.”
SGC Partners, a venture capital firm established in 2021, currently manages funds totaling 310 billion won. It invests in startups in the environment, energy, artificial intelligence (AI) and deep-tech sectors, and is expanding its portfolio into new business areas, recently participating as a co-GP in the Gunsan AI data center project.

[email protected] Choi A-young Reporter